Optimal

Overview

The Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products via a sub-agreement with CHAI (Project Optimal) is a follow-up to the Unitaid-funded SPAAN Project (August 2019 – July 2020). SPAAN streamlined and accelerated the introduction of new, child-friendly ARV formulations by focusing on plans for solid formulations of LPV/r and the DTG 50 mg tablet, as well as future plans to introduce DTG dispersible formulations. Building on the success of that project, Project Optimal aims to (1) streamline and accelerate the transition to WHO-recommended optimal pediatric ARV formulations, focusing on DTG 10mg dispersible tablets and LPV/r solid formulation’s, (2) strengthen information, supply chain, service delivery, and pharmacovigilance systems for pediatric ARVs, and (3) strengthen differentiated service delivery models of care for children, focusing on multi-month dispensing (MMD) and facility-based, family-centered models that include children < 5 years of age.

Funded by CHAI